Investors appear skeptical about the FDA's request for additional information from Sarepta...

|About: Sarepta Therapeutics, Inc. (SRPT)|By:, SA News Editor

Investors appear skeptical about the FDA's request for additional information from Sarepta Therapeutics (SRPT) regarding the company's Duchenne muscular dystrophy drug. CEO Chris Garabedian says he does not anticipate "an impact on SRPT's ongoing activities" from the FDA's request or from the delay it occasioned in the accelerated approval submission process. Nonetheless, the shares are -6.22% premarket.